Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...
Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...
Scilex宣布与FDA成功完成了II期会议，达成了一致意见，为SP-103（局部利多卡因系统）5.4%的治疗方案前进到NDA提供了路径，待完成III期试验。
Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of Chronic Neck Pain Associated With Muscle Spasms
Scilex宣布与FDA成功完成了II期会议，达成了一致意见，为SP-103（局部利多卡因系统）5.4%的治疗方案前进到NDA提供了路径，用于治疗伴有肌肉痉挛的慢性颈部疼痛。
资讯热榜
更新时间